- Home
- GNTA vs EDAP Comparison
GNTA vs EDAP Comparison
Compare GNTA & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- EDAP
- Stock Information
- Founded
- GNTA 2014
- EDAP 1979
- Country
- GNTA Italy
- EDAP France
- Employees
- GNTA N/A
- EDAP N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GNTA Health Care
- EDAP Health Care
- Exchange
- GNTA Nasdaq
- EDAP Nasdaq
- Market Cap
- GNTA 96.0M
- EDAP 81.6M
- IPO Year
- GNTA 2021
- EDAP 1997
- Fundamental
- Price
- GNTA $3.98
- EDAP $2.34
- Analyst Decision
- GNTA Strong Buy
- EDAP Strong Buy
- Analyst Count
- GNTA 1
- EDAP 1
- Target Price
- GNTA $25.00
- EDAP $19.00
- AVG Volume (30 Days)
- GNTA 21.3K
- EDAP 68.6K
- Earning Date
- GNTA 01-01-0001
- EDAP 11-07-2024
- Dividend Yield
- GNTA N/A
- EDAP N/A
- EPS Growth
- GNTA N/A
- EDAP N/A
- EPS
- GNTA N/A
- EDAP N/A
- Revenue
- GNTA N/A
- EDAP $70,722,730.00
- Revenue This Year
- GNTA N/A
- EDAP $6.96
- Revenue Next Year
- GNTA N/A
- EDAP $15.53
- P/E Ratio
- GNTA N/A
- EDAP N/A
- Revenue Growth
- GNTA N/A
- EDAP 12.17
- 52 Week Low
- GNTA $2.20
- EDAP $2.00
- 52 Week High
- GNTA $7.28
- EDAP $8.50
- Technical
- Relative Strength Index (RSI)
- GNTA 34.55
- EDAP 49.88
- Support Level
- GNTA $3.51
- EDAP $2.12
- Resistance Level
- GNTA $5.45
- EDAP $2.29
- Average True Range (ATR)
- GNTA 0.55
- EDAP 0.16
- MACD
- GNTA -0.10
- EDAP 0.01
- Stochastic Oscillator
- GNTA 13.90
- EDAP 41.13
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.